69 / 79
page 70
6th ICHNO
6
th
ICHNO Conference
International Conference on innovative approaches in Head and Neck Oncology
16 – 18 March 2017
Barcelona, Spain
__________________________________________________________________________________________
randomized trial with a large sample size should be
conducted to confirm our results.
PO-146 Radiotherapy in elderly patients aged ≥ 70 years
with head and neck squamous cell carcinoma
E. Metcalfe
1
, D. Etiz
1
, A. Ozen
1
1
Osmangazi University Medical Faculty, Radiation
Oncology, Eskisehir, Turkey
Purpose or Objective
To review survival outcomes and analyse the treatment
tolerance in elderly patients aged ≥ 70 years with head
and neck squamous cell carcinoma (HNSCC) treated with
radiotherapy (RT).
Material and Methods
Patients aged ≥ 70 years treated with radiotherapy
between 2005-2016 for HNSCC were retrospectively
identified. 2D conventional and 3D conformal
radiotherapy technique was used until 2015, and
subsequently patients were treated with IMRT. Outcome
measures were 1 and 2 year disease free survival (DFS),
and overall survival (OS). Univariate and multivariate
analyses was performed for survival outcomes.
Results
A total of 96 consecutive ≥70 years and patients were
identified. Median follow up was 26 (range 3-125) months.
Median age was 78 years (range 70-97). 77/96 (80%) were
male and 30/96 (31%) were ≥80 years old. The primary
tumour location was larynx 63 (66%), pharynx 12 (13%),
oral cavity 11 (12%), other 10 (9%). Breakdown of TNM
stage were: T1 29 (30%), T2 15 (16%), T3 23 (24%), T4 29
(30%), N0 69 (72%), N1 11 (12%), N2 13 (14%), N3 3 (2%).
Surgery involved in 25 (26%) patients followed by adjuvant
RT. Curative RT was delivered to 61/96 (64%) patients with
median 66 (range 62-70) Gy and palliative RT were to
10/96 (10%) patients with median and 30 (range 30-39) Gy.
2D conventional, 3D conformal technique and IMRT were
used in 11 (12%), 60 (62%) and 25 (26%) patients
respectively. Concurrent platinum chemotherapy was
given to 6 (6%) of patients. Acute toxicity was seen in 86
(90%) patients (grade-1 75%, grade-2 10%, grade-3 5%).
Median 3 (range 1-10) days off in the treatment in 61 (64%)
patients. 82/96 (85%) patients completed their RT scheme
without any interruption.
71 (74%) patients experienced complete response. 1 and 2
years DFS for the all cohort was 61% and 56%, and OS was
84% and 78%, respectively. Radiotherapy technique did not
significantly affect the survival. In univariate analysis,
gender (female, p=0.01), advanced T stage (T2-4,
p=0.001) and N stage (N2-3, p=0.003) for DFS, and older
age (≥80 years, p=0.008), and advanced N stage (N2-3,
p=0,01) for OS had found the negative impact (Figure 1).
Stage 2-4 disease was found a poor prognostic factor for
DFS in multivariate analysis (p<0,05, Exp(β)=0,190, 95% CI
for Exp(β)=0,065-0,556).
Conclusion
Radiotherapy provides high rates of tumor control and
survival with reasonable toxicity, although the very low
concurrent chemotherapy usage in elderly patients aged
≥70 with HNSCC. Radiotherapy requires careful schedule
selection and follow-up in elderly patients aged ≥ 80
years.
PO-147 The ELAN program: Customised treatment of
SCCHN elderly patients according to geriatric
assessment
J. Guigay (France), C. Ortholan, H. Le Caer, S. Renard-
oldrini, X. Sun, L. Mayache-badis, L. Geoffrois, J.
Fayette, C. Even, D. Vansteene, Y. Pointreau, D. Schwob,
N. Vintonenko, C. Michel, J. Bourhis, A. Auperin, C.
Mertens
1
Centre Antoine Lacassagne, Medical Oncology,
Nice, France
2
Princesse Grace Hospital, Radiotherapy, Monaco,
Monaco
3
Centre Hospitalier de la Dracénie, Medical Oncology,
Draguignan, France
4
Institut de Cancérologie de Lorraine, Radiotherapy,
Vandoeuvre-lès-Nancy, France
5
CHBM Site du Mittan, Radiotherapy, Montbéliard,
France
6
Gustave Roussy, Medical Oncology, Villejuif, France
7
Institut de Cancérologie de Lorraine, Medical Oncology,
Vandoeuvre-lès-Nancy, France
8
Centre Léon Bérard, Medical Oncology, Lyon, France
9
Institut de Cancérologie de l’Ouest René Gauducheau,
Medical Oncology, Nantes, France
10
Clinique Victor Hugo, Medical Oncology, Le Mans,
France
11
Gustave Roussy, Datamanagement, Villejuif, France
12
GORTEC, Clinical Research, Tours, France
13
GORTEC, Clinical Research, Nice, France
14
GORTEC, Radiotherapy, Tours, France
15
Gustave Roussy, Biostatistics, Villejuif, France
16
Institut Bergonié, Geriatry, Bordeaux, France
Purpose or Objective
Thirty percent of SCCHN occur in patients (pts) more than
70y; the main challenge in these pts is to balance the
benefit/risk treatment ratio regarding tumor related
symptoms. However, these pts are usually excluded from